| Control donors | COVID-19 patients | P-value |
---|---|---|---|
(n = 8) | (n = 10) | ||
Age, years | 47.25 (± 8.31) | 45.80 (± 13.76) | 0.797a |
Gender, male | 4 (50%) | 6 (60%) | 0.520b |
Comorbidities | Â | ||
Hypertension | 0 (0%) | 3 (30%) | Â |
Diabetes | 0 (0%) | 2 (20%) | Â |
Cancer | 0 (0%) | 1 (10%) | Â |
Hyperlipidemia | 3 (37.5%) | 0 (0%) | Â |
Heart disease | 0 (0%) | 0 (0%) | Â |
DVT | 0 (0%) | 0 (0%) | Â |
Symptom | Â | ||
Fever | 0 (0%) | 8 (80%) | Â |
Cough | 0 (0%) | 8 (80%) | Â |
Expectoration | 0 (0%) | 5 (50%) | Â |
Sore throat | 0 (0%) | 3 (30%) | Â |
Fatigue | 0 (0%) | 1 (10%) | Â |
Muscle ache | 0 (0%) | 2 (20%) | Â |
Chest tightness | 0 (0%) | 0 (0%) | Â |
Nausea | 0 (0%) | 1 (10%) | Â |
Diarrhea | 0 (0%) | 0 (0%) | Â |
Physical signs | Â | ||
Respiratory rate |  | 20 (18–20) |  |
Heart rate |  | 85 (75–92) |  |
Laboratory findings on admission | |||
CRP, mg/dL | 1.41 (± 1.78) | 22.51 (± 25.65) | 0.029a |
Leukocytes, × 109/L | 5.39 (± 1.34) | 4.85 (± 1.54) | 0.440a |
Neutrophils, × 109/L | 3.10 (± 0.85) | 3.00 (± 1.33) | 0.846a |
Lymphocytes, × 109/L | 1.88 (± 0.66) | 1.27 (± 0.28) | 0.037a |
Platelet count, × 109/L | 294.25 (± 44.52) | 212.40 (± 70.70) | 0.009a |
MPV, fl | 10.06 (± 0.81) | 9.78 (± 0.51) | 0.407a |
PT, S | 12.31 (± 0.75) | 13.73 (± 0.25) | 0.399a |
APTT, S | 36.40 (± 4.19) | 45.47 (± 5.17) | 0.001a |
Fibrinogen, mg/Dl | 2.86 (± 0.54) | 4.76 (± 0.87) |  < 0.001a |
ALT, U/L | 21.25 (± 10.47) | 26.70 (± 5.76) | 0.215a |
Creatinine, μmol/L | 60.34 (± 12.74) | 66.75 (± 21.00) | 0.440a |